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Background
The South African (SA) National Department of Health (DoH) 
released new guidelines for the management of HIV/AIDS in April 
2010. We discuss here controversial issues and operational challenges 
in the guidelines; the stimulation of debate and contributing to future 
guidelines; the timing of initiation of antiretroviral treatment, scope 
and timing of laboratory monitoring and testing of concomitant 
conditions, operational challenges such as paediatric HIV treatment 
and nurse-driven care, and procedures relating to the guidelines such 
as the need for transparency of the guideline committee and the 
standard of evidence used to develop the guidelines. We welcome 
comment and sharing of further insights that will contribute to future 
guidelines.
Our motivation stems from the facts that South Africa’s HIV epidemic 
is not abating; its Millennium Development Goals are not being met; 
and child and maternal mortality are worse than they were in 1990.1 
The Department of Virology of the University of Pretoria convened a 
meeting of private and public health practitioners in June 2010 to debate 
the DoH’s new antiretroviral treatment (ART) guidelines.
Are the goals realistic? Are these 
‘national’ guidelines and do they 
address private and public health 
sector needs equally?
Feasibility and standardisation
The goals are laudable, their scope daunting. But are they achievable? 
According to the spokesperson for the SA National AIDS Council, 
‘The purpose [of the guidelines] is to bring these into line with 
international recommendations and ensure the use of more efficacious 
drugs.’2 How will these goals be implemented and progress and 
success measured?
Guidelines for the public or private sector or 
both?
The guidelines focus on needs of the public health sector, whose 
huge numbers dwarf private-sector HIV medicine. But both systems 
must find common ground as health borders are porous. Drugs and 
tests must be identical or similar. Guidelines should inform and aid 
integration e.g. when the guidelines do not refer to the use of viral 
genotyping or baseline hepatitis B screening, does this mean that 
these tests are unavailable or unnecessary? National guidelines must 
inform health workers broadly and wisely.
Transparency
International guidelines are referenced throughout and 
recommendations graded. The panel of experts responsible for 
drafting the guideline is identified. A guideline must be seen to be 
objective, truthful, credible and relevant. Since we could not locate 
information about the panel of experts from the ‘guideline’ website,3 
we question the adequacy of representation from all stakeholders, 
including the private sector.
When should ART be started?
Starting CD4 level
The guidelines recommend that therapy in adults be started at 
CD4 ≤200 cells/µl except in pregnancy and active tuberculosis, 
where therapy can now be started at CD4 ≤350 cells/µl. A stated 
objective is to ‘ensure timely initiation of antiretroviral drugs’. At the 
2009 International AIDS Society (IAS) Conference, the president 
of the society stated that CD4 ≤350 cells/µl should be considered 
a ‘minimum standard of care’ for commencing ART, which is 
supported by the World Health Organization (WHO), European 
and British AIDS societies.  The IAS-USA panel recommend higher 
levels: ≤500 CD4 cells/µl.4
Risks of delaying ART
The outcomes of more than 45 000 patients starting ART since 1997, 
from 18 observational cohorts in Europe and North America, were 
reviewed. Delaying ART until CD4 251 - 350 cells/µl demonstrated 
a 28% (HR 1.28, 95% CI 1.04 - 1.57) increased risk of AIDS and 
death compared with those starting at higher levels i.e. 351 - 450 
cells/µl.5 This finding suggested that CD4 of 350 cells/µl be the Corresponding author: T Rossouw (theresa.rossouw@up.ac.za)
Theresa Rossouw is affiliated to the Department of Family 
Medicine, University of Pretoria; Karin Richter to the Department 
of Medical Virology, University of Pretoria, and the National Health 
Laboratory Service; Des Martin to the Department of Medical 
Virology, University of Pretoria, and Toga Molecular Laboratory; 
Theuns Avenant to the Department of Paediatrics, University 
of Pretoria; and David Spencer to the Toga Clinical Unit, Toga 
Molecular Laboratory, Johannesburg.
ISSUES IN MEDICINE
The 2010 South African guidelines for the management of HIV 
and AIDS: A review
Theresa Rossouw, Karin Richter, Des Martin, Theuns Avenant, David Spencer
Table I. Goals of the 2010 ART guidelines
•    Achieving best possible health outcomes in the most cost-efficient 
manner
•   Implementation of nurse-initiated ARV-treatment
•    Decentralisation of service delivery to primary health care (PHC) 
facilities
•    Integration of services for HIV with TB, maternal and child health 
(including prevention of mother to child transmission), sexual 
and reproductive health, and wellness programmes
•   Earlier diagnosis of HIV
•   Prevention of HIV disease progression
•   Prevention of AIDS-related deaths
•   Retention of patients on lifelong therapy
•    Prevention of new infections among children, adolescents and 
adults
•   Mitigation of the impact of HIV/AIDS on society
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minimum threshold for starting ART, and initiated the international 
debate about the benefits of starting even earlier. These results have 
been reproduced in the developing world: in Haiti, adults with CD4 
counts between 200 and 350 cells/µl were randomised to start ART 
immediately or defer treatment until CD4 had dropped below 200 
cells/µl. A fourfold increase in mortality in the deferred arm led to the 
premature discontinuation of this study on ethical grounds.6
Delay in starting ART increases disease- and treatment-related 
morbidity and costs: the effects of opportunistic disease are more 
severe, drug toxicity is more frequent, and the immune reconstitution 
inflammatory syndrome (IRIS) more overwhelming.7-9 IRIS is a 
particular problem in southern Africa where concomitant infections 
such as tuberculosis and cryptococcal meningitis are frequent and 
initiation is late. The guidelines should specifically address the timing 
of ART initiation in the face of active opportunistic infections and the 
management of IRIS, including when steroid use is warranted, but is 
silent on these issues.
Late ART initiation is linked to the risk of AIDS- and non-AIDS-
defining malignancy,10 drug resistance9 and increased risk of failure 
to reconstitute the immune system.11 Patients starting ART at CD4 
≥350 cells/µl are more likely to achieve normal CD4 counts within 4 
years of starting treatment.
Economics of starting ART at earlier CD4 
levels
Why would the DoH want to delay the start of ART? Costs and a 
limited capacity are probable constraints. Nevertheless, there are 
compelling data from cost-effectiveness studies and mathematical 
modelling that the early start of ART in South Africa can be cost-
effective in adults and children, even at levels >350 cells/µl.12 There 
are caveats: poor adherence, adverse events and loss to follow-up can 
increase costs and undermine the investment. Increased caseloads 
would demand more from a tired and demoralised health sector. But 
few South Africans currently present with CD4 counts >200 cells/
µl. Raising the CD4 bar to 350 cells/µl is unlikely to swamp our HIV 
clinics. Innovative and supportive handling of this challenge could 
catalyse improvement of the delivery of care to all South Africans.
Statistical modelling shows that earlier treatment would not 
have had a major impact on the number of patients receiving ART. 
If patients initiate treatment at a threshold of ≤200 cells/µl, the 
number of patients on ART would increase by approximately 233% 
from roughly 950 000 in 2009 to approximately 3.16 million by 
2016. Adoption of the new South African guidelines would result 
in a further increase of 14%, and the WHO guidelines in only an 
additional 10% by 2016.13 Some of our poorer neighbours, such as 
Botswana and Zambia, have already adopted these guidelines, and 
a few others, such as Malawi, Tanzania and Nigeria, have conducted 
WHO-supported feasibility studies and announced plans to roll out 
the new WHO guidelines by mid-2011.
Laboratory monitoring: Which tests? 
How often, if at all?
Utilitarian concerns, limited resources
Laboratory monitoring is concerned with the virus, the immune 
response and toxicity. Insights gained from such monitoring have 
led to enormous achievements. However, tests are expensive and 
difficult to regulate, and results frequently ignored. Would money be 
spent more efficiently on scaling up access to ART? Perhaps with this 
in mind, can the guidelines significantly reduce baseline and follow-
up tests? Will fewer viral loads lead to the impaired management of 
adherence and resistance? Will less monitoring mean greater delay in 
diagnosing adverse events? Will this compromise patients’ health?
Laboratory tests in Africa: are these 
necessary?
The Development of AntiRetroviral Therapy in Africa (DART) 
study addressed the difference between clinically driven monitoring 
(CDM) and laboratory and clinical monitoring (LCM). No ‘real-time’ 
viral load (VL) results were provided in either, but CD4 results were 
reported to each group and haematology and chemistry data could 
be accessed in the CDM arm if ‘clinically indicated’. Grade 3 and 4 
events were provided immediately irrespective of the group. This 
important aspect of the study has been overlooked by policymakers, 
who reduced laboratory monitoring based on the DART study. Even 
though overall survival was excellent after 5 years, 28% CDM v. 21% 
LCM participants had a new WHO stage 4 event or died (6·94; 95% 
CI 6·33 - 7·60 and 5·24; 4·72 - 5·81 per 100 person-years, respectively). 
The absolute difference of 1·70 per 100 person-years (95% CI 0·87 
- 2·54) translated into a significant relative HR of 1·31 (95% CI 
1·14 - 1·51; p=0·0001).14 Worryingly, the proportion of patients with 
HIV RNA >1000 copies/ml increased from 15% at 24 weeks to 24% 
at 48 weeks; 18 (58%) of 31 genotyped samples at 24 weeks had ≥1 
major nucleoside reverse transcriptase inhibitor (NRTI)-associated 
mutation, compared with 41 of 47 (87%) at 48 weeks. A mean of 2.0 
(95% CI 1.3 - 2.8) thymidine analogue mutations (TAMs) developed 
between weeks 24 and 48.15
VL monitoring
The guideline discarded baseline VL monitoring. The first VL is drawn 
at 6 months on therapy, repeated at 12 months, and thereafter annually. 
Baseline VL is related to risk of drug resistance and death, progression 
of disease, occurrence of opportunistic diseases (particularly cancers), 
and response to therapy.10 When the starting-point of a journey is 
unknown, progress is difficult to map. After taking ART for 6 months, 
the VL will be either detectable or undetectable. If undetectable, either 
the virus is well suppressed, or undetectable from the start i.e. an élite 
controller, an unusual recombinant form, or a false-positive HIV 
ELISA. How would one know?
If the VL is detectable at 6 months, adherence counselling may be 
too late. Non-adherence can lead to resistance to the non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) and 3TC within 4 - 8 
weeks. All that is needed is a single-point mutation. Longer time 
spent on a failing regimen leads to greater numbers of mutations 
and more complex resistance.16 Early VL monitoring, 6 - 12 weeks 
after starting ART, provides the trigger to early intervention and 
prevention of resistance. Frequent VL monitoring is particularly 
useful in the first months after starting ART, and the IAS-USA 2010 
guidelines recommend repeating VL 2 - 8 weeks after initiation, every 
4 - 8 weeks until suppressed, and then every 3 - 4 months for at least 
the first year.4
Monitoring of liver, renal and hepatitis B 
status
Given the inherent risks of ART – particularly when initiating 
treatment at advanced stages of infection – the guidelines make 
little provision for toxicity monitoring. Tenofovir (TDF) has been 
introduced into first-line therapy. Reliable suppression of both 
hepatitis B and HIV in those with dual infection, and the maintenance 
of normal renal function, need mentioning. The prevalence of HIV-
HBV co-infection in South Africa is estimated to be 6 - 17%.17 TDF, 
FTC and 3TC share activity against HBV, and monotherapy with these, 
will lead to HBV drug-resistance. Stopping HBV-suppressive therapy 
i.e. discontinuing TDF/3TC or TDF/FTC, has been associated with 
severe ‘flare-ups’ of the underlying hepatitis B.18 ART active against 
HBV therefore must be continued even if HIV virological failure has 
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occurred. The recommendation that HBV testing is advised before 
TDF is discontinued lacks emphasis. The guidelines recommend 
limiting baseline HBV testing to patients with significantly elevated 
liver transaminases, but a substantial proportion of co-infected 
patients (84.2% in a South African study) have normal levels at 
baseline.17 Baseline HBV testing for all may be more prudent.
TDF causes renal toxicity as early as 5 weeks19 in 1.5 - 2.3% of 
patients. The ‘guidelines’ recommend that creatinine clearance is 
checked at months 3 and 6 and then annually, but earlier monitoring 
is needed. TDF has also been linked to the development of Fanconi 
syndrome, yet no electrolyte monitoring is advised. Glucosuria and 
proteinuria may direct the caregiver to a renal problem, and routine 
urine dipstix monitoring should be encouraged.
The second concern is the lack of liver enzyme monitoring on 
NVP. ALT testing is only recommended if a rash develops on NVP 
and, since this is an early occurrence, it will not warn of mid-term or 
late-onset hepatotoxicity. Liver toxicity rates vary between 0 and 27% 
and are higher in women. There is significant concern about NVP 
toxicity since the guidelines recommend the use of NVP in pregnant 
women with CD4 counts ≤350 cells/µl. NVP has been avoided in 
women with nadir CD4 counts >250 cells/µl because of the risk of 
fatal hepatotoxicity.20 Despite recent studies not confirming this 
risk,21 we advise caution and more frequent ALT monitoring since 
deaths have been reported, mostly in the higher CD4 category (>250 
cells/µl) and mostly among women.
Genotyping, ART regimen sequencing and 
third-line options
Survival data suggest that 22.5 years, perhaps more, can be added 
to the life of someone on ART.22 Will current treatments last that 
long? The weakness of first-line treatment is the low genetic barrier 
to resistance. Only 1 or 2 key resistance mutations may confer drug 
resistance to that regimen and to other agents, thereby limiting 
subsequent treatment options. Early drug failure is a risk, and delay 
in switching to second-line treatment will also increase the degree 
of resistance. Therefore, much second-line therapy may effectively 
be boosted protease inhibitor monotherapy. It will be difficult to 
know without genotyping, which is expensive, yet is an essential 
guide in the planning of ‘next’ therapies. While first- and second-line 
regimens can remain largely generic for now, third-line and salvage 
therapies must be tailored to the recipient unless new classes of ARV 
are made available.
The guidelines advise that those failing second-line treatment 
be referred to a specialist. But there are too few specialists and an 
alternative plan is needed. Patients and their caregivers will soon 
demand third-line treatments. Via application to the Medicines 
Control Council, private-sector patients can access new drugs, which 
are expensive, and local pricing can only be reviewed (and hopefully 
reduced) upon registration in this country. Placing these drugs into a 
planned schedule will start to regulate their use wisely and focus on 
answers to third-line options. In this regard, the guidelines require 
closer approximation to international counterparts.
Managing the epidemic: 
Decentralising care, empowering 
nurses
With 5.7 million or more HIV-infected individuals in South Africa, 
doctors alone cannot provide sufficient care. It makes sense for 
nurses and ‘clinical associates’ to broaden this base, as in Malawi and 
Botswana. In a randomised trial (N=812) in South Africa, doctor-
managed ART-related care was compared with nurse-managed 
care.23 Nurses were as good as doctors in providing care. The actively 
sick were excluded from recruitment, and this study therefore lends 
support to nurses in the caring of well HIV patients. Doctors would 
be better used caring for the sick. Of concern was the alarmingly 
high level of cumulative failure at week 120 – 48% (nurse group) and 
44% (doctor group) – which suggests that neither doctors nor nurses 
intervene adequately to prevent treatment failure, and lends further 
support to more frequent VL monitoring. Based on VL results, 
a nurse can give step-up adherence counselling and retest after 1 
month. If re-suppression of the virus has not taken place, referral to 
a doctor is recommended.
The role of nurses as caregivers in the HIV epidemic requires clear 
defining. Health professions councils must provide registration, legal 
protection and ensure adequate skills. Sick patients will need referral 
for assessment and care by doctors and, once well, be referred to 
nurse-level care. Perhaps some nurses will be trained to manage 
various non-life-threatening medical conditions in the community. 
But nursing care will only be as good as the next tier of support. At 
present, the South African public health system shows little evidence 
of the resilience and goodwill that this venture will demand. The 
guidelines give no detail in this regard and are also silent on the role 
of, and guidelines for, clinical mentoring programmes for caregivers.
Paediatric care
Changes in the paediatric guidelines have brought the private 
and public sector management of HIV-infected children closer 
together. Although the Prevention of Mother to Child and Paediatric 
Treatment guidelines are steps in the right direction, concerns exist 
about their implementation. Children often present with end-stage 
disease. The focus should be shifted to active case finding at primary 
health care level. Clinic staff are often reluctant to initiate children on 
ARVs, most probably because of inadequate training and the large 
number of adults requiring care. Support for clinics in this regard 
should be urgently addressed.
Prevention strategies
The guidelines should be augmented by greater emphasis on 
prevention strategies. Prevention of infections (such as pneumonia, 
tuberculosis, HBV and HPV) through treatment or vaccination 
should be addressed along with discussion of screening protocols 
for cervical carcinoma. Specific prevention of HIV transmission 
deserves attention i.e. condoms, circumcision, microbiocides and 
ART. Prevention of drug toxicity and drug interactions and contra-
indications also require more space.
Table II. Key recommendations from the group
•   More transparency of the guideline process in the future
•   Inclusion of all stakeholders
•   Earlier commencement of ART
•    Advice specifically on the timing of ART initiation in the face of 
active opportunistic infections
•    More comprehensive laboratory monitoring at baseline and on 
therapy for toxicity and treatment response, specifically more VL 
monitoring
•   Recognition of the special case of hepatitis B in our population
•    Recognition of requirements for 3rd-line therapy and the rational 
use of specialised tests e.g. genotyping
•    Empowerment of nurse practitioners and development of task 
shifting and mentoring protocols
•   Integration of paediatric needs into the new guidelines.
•    More emphasis on preventive aspects – immunisations, INH 
preventive therapy, treatment as prevention
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Parenteral artesunate should be used in preference to quinine for 
the treatment of severe malaria, given its significant mortality and 
safety benefits. As the product has not yet been registered for use 
in South Africa, the Parenteral Artesunate Access Programme has 
been launched to reduce malaria-related mortality. Severe malaria 
is a medical emergency that requires prompt treatment to prevent 
death, which occurs in 10 - 50% of patients.1 Based on high-quality 
evidence, the World Health Organization (WHO) now strongly 
recommends intravenous (IV) artesunate in preference to IV quinine 
for the treatment of severe malaria in adults.2
Mortality and safety benefit
Artesunate, an artemisinin derivative, is highly effective in the 
treatment of malaria owing to its rapid parasite clearance, broad stage 
specificity and easy, safe administration compared with quinine.
The South-East Asian Quinine Artesunate Malaria Multicentre 
Randomised Controlled Trial (SEAQUAMAT) compared parenteral 
artesunate and quinine in 1 461 patients with severe Plasmodium 
falciparum malaria with death as the primary endpoint. The mortality 
rate was 15% in the artesunate arm compared with 22% in the quinine 
arm, with an absolute mortality risk reduction between study sites 
ranging from 5 - 9%. Therefore, the numbers needed to treat to save 
one life ranged from 11 - 20 patients. Treatment with artesunate was 
well tolerated, whereas quinine was associated with hypoglycaemia 
(relative risk (RR) 3.2, 1.3 - 7.8; p=0.009).3 A Cochrane systematic review 
that informed the WHO treatment guidelines favoured the use of IV 
artesunate over quinine, with a 38% decrease in the risk of death (RR 0.62, 
95% confidence interval (CI) 0.51 - 0.75; 1 938 participants, 6 trials).4
The challenge
The Global Health Malaria Elimination Group has set the ambitious 
goal of eradicating malaria from the planet by 2050.5 Together with 
Namibia, Botswana and Swaziland, South Africa supports the WHO 
Roll Back Malaria (RBM) initiative in Africa and aims to eliminate Corresponding author: K Barnes (karen.barnes@uct.ac.za)
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